283 GSK Annual Report 2016 Strategic report Governance and remuneration Financial statements Investor information Glossary of terms Terms used in the Annual Report US equivalent or brief description Accelerated capital allowances T ax allowance in excess of depreciation arising from the purchase of xed assets that delay the charging and payment of tax.
The equivalent of tax depreciation.
American Depositary Receipt ADR Receipt evidencing title to an AD S. Each GSK ADR represents two Ordinary Shares.
American Depositary Shares ADS Listed on the New York Stock Exchange: represents two Ordinary Shares.
Basic earnings per share Basic income per share.
Called up share capital Ordinary Shares, issued and fully paid.
CER growth Growth at constant exchange rates.
Corporate Integrity Agreement CIA In 20 12, the company entered into a settlement with the US Federal Government related to past sales and marketing practices.
As part of the settlement the company entered into a Corporate Integrity Agreement with the US Department of Health and Human Services.
Currency swap An exc hange of two currencies, coupled with a subsequent re-exchange of those currencies, at agreed exchange rates and dates.
Dened benefit plan Pension plan with specic employee benets, often called final salary scheme.
Dened contribution plan Pension plan with specic contributions and a level of pension dependent upon the growth of the pension fund.
Derivative financial instrument A financial instrument that derives its value from the price or rate of some underlying item.
Diluted earnings per share Diluted income per share.
Employee Share Ownership Plan Trusts Trusts established by the Group to satisfy share-based employee incentive plans.
Equity Shareholders funds Shareholders equity.
Freehold Ownership with absolute rights in perpetuity.
The Group GlaxoSmithKline plc and its subsidiary undertakings.
GSK GlaxoSmithKline plc and its subsidiary undertakings.
Hedging The reduction of risk, normally in relation to foreign currency or interest rate movements, by making off-setting commitments.
Intangible xed assets Assets without physical subst ance, such as computer software, brands, licences, patents, know-how and marketing rights purchased from outside parties.
Novartis transaction T he three-part inter-conditional transaction with Novartis AG involving the Consumer Healthcare, Vaccines and Oncology businesses completed on 2 March 2015.
Ordinary Share A fully paid up ordinary share in the capital of the company.
profit attributable to shareholders Net income.
Share capital Ordinary Shares, capital stock or common stock issued and fully paid.
Share premium account Additional paid-up capital or paid-in surplus not distributable.
Shares in issue The number of shares outstanding.
Subsidiary An entity in which GSK exercises control.
UK Corporate Governance Code As required by the UK Listing Authority, the company has disclosed in the Annual Report how it has applied the best practice corporate governance provisions of the Financial Reporting Councils UK Corporate Governance Code.
284 GSK Annual Report 2016 Index Page Page Accountability 97 Major restructuring costs 175 Accounting principles and policies 162 Movements in equity 201 Acquisitions and disposals 205 Net debt 198 Adjustments reconciling profit after tax to operating New accounting requirements 168 cash ows 203 Nominations Committee Report 94 Annual General Meeting 2017 266 Non-controlling interests 209 Approach to tax 55 Non-controlling interests in ViiV Healthcare 58 Assets held for sale 188 Non-Executive Directors fees 126 Associates and joint ventures 177 Notes to the financial statements 162 Audit and Risk Committee Report 97 Operating profit 173 Cash and cash equivalents 188 Other intangible assets 184 CEOs statement 5 Other investments 187 Chairmans statement 4 Other non-current assets 187 Chairmans Governance statement 80 Other non-current liabilities 198 Chairmans Remuneration report statement 112 Other operating income 173 Commitments 211 Other provisions 197 Consolidated balance sheet 159 Our behaviour 46 Consolidated cash ow statement 161 Our Board 82 Consolidated income statement 158 Our business model 12 Consolidated statement of changes in equity 160 Our global marketplace 8 Consolidated statement of comprehensive income 158 Our integrated approach 6 Consumer Healthcare 34 Our people 48 Consumer Healthcare products and competition 252 Our planet 50 Contingent consideration liabilities 208 Our strategy priorities 14 Contingent liabilities 199 Pay for performance 119 Corporate Executive Team 86 Pensions and other post-employment benets 189 Corporate governance 79Pharmaceuticals 20 Corporate Responsibility Committee Report 108 Pharmaceutical products, competition and Critical accounting policies 76 intellectual property 250 Directors and senior management 134Pipeline 247 Directors interests in shares 127 Post balance sheet events 224 Directors statement of responsibilities 148,232 Presentation of the financial statements 162 Dividends 180,265 Principal Group companies 225 Donations to political organisations and Principal risks and uncertainties 18,253 political expenditure 271 Property, plant and equipment 181 Earnings per share 180 Quarterly trend 240 Employee costs 174 Reconciliation of net cash ow to movement in net debt 204 Employee share schemes 223Registrar 268 Exchange rates 168 Related party transactions 203 Executive Director remuneration 116 Relations with shareholders 106 Finance expense 176 Remuneration governance 124 Finance income 176 Remuneration policy summary 137 Financial calendar 265 Remuneration report 112 Financial instruments and related disclosures 212 Reporting framework 57 Financial position and resources 72 Research and development 12,24,32,38 Financial statements of GlaxoSmithKline plc, prepared Responsible business 40 under UK GAAP 232 Segment information 169 Five year record 244 Share capital and control 263 Glossary of terms 283 Share capital and share premium account 200 Goodwill 182 Share price 263 Group companies 272 Shareholder information 263 Group financial review 52 Shareholder services and contacts 268 Health for all 44Taxation 178 How we manage risks 18 Tax information for shareholders 266 Independent Auditors report 149,233 Trade and other payables 189 Inventories 188 Trade and other receivables 188 Investments in associates and joint ventures 186 US law and regulation 270 Investor relations 269Vaccines 28 Key accounting judgements and estimates 166 Viability statement 56 Key performance indicators 16 Leadership and effectiveness 88 Legal proceedings 226 GSK Annual Report 2016 About GSK Brand names GlaxoSmithKline plc was incorporated as Brand names appearing in italics throughout this report are trade marks either owned by and or licensed to GSK an English public limited company on or associated companies, with the exception of Prolia, owned by Amgen, Zofran, owned by Novartis, Trumenba and Mencevax, owned by Pzer, Treximet, owned by Pernix 6 December 1999.
We were formed by a merger Ireland, Lucozade and Ribena, owned by Suntory and Nimenrix, a trade mark of GSK licensed to Pzer.
between Glaxo Wellcome plc and SmithKline Acknowledgements Beecham plc.
GSK acquired these two English Design Friend www.
com companies on 27 December 2000 as part of Printing Pureprint Group, ISO 14001. the merger arrangements.
FSC certied and Carbon Neutral.
Paper This Annual Report is printed on Amadeus 100 Silk, Our shares are listed on the London Stock Exchange a 100% recycled paper with full FSC certication.
All pulps used are made from 100% fide-inked, post-consumer waste and are elemental chlorine free.
and the New York Stock Exchange.
The manufacturing mill holds the ISO 14001 and EU Ecolabel certicates for environmental management.
com Download PDFs: Annual Report 2016 Form 20-F Responsible Business Supplement 2016 Cautionary statement regarding Such factors include, but are not limited to, those The assumptions for the Groups revenue and earnings forward-looking statements discussed under Principal risks and uncertainties on expectations assume no material mergers, acquisitions, pages 253 to 262 of this Annual Report.
Any forwarddisposals, litigation costs or share repurchases for the The Groups reports led with or furnished to the US looking statements made by or on behalf of the Group Company: and no change in the Groups shareholdings Securities and Exchange Commission SEC, including speak only as of the date they are made and are based in ViiV Healthcare or Consumer Healthcare.
They also this document and written information released, or upon the knowledge and information available to the assume no material changes in the macro-economic and oral statements made, to the public in the future by or Directors on the date of this Annual Report.
on behalf of the Group, may contain forward-looking statements.
Forward-looking statements give the Groups A number of adjusted measures are used to report The Groups expectations assume successful delivery current expectations or forecasts of future events.
An the performance of our business.
These measures are of the Groups integration and restructuring plans over investor can identify these statements by the fact that dened on page 57 and a reconciliation of core results the period 2016-2020.
Material costs for investment in they do not relate strictly to historical or current facts.
to total results is set out on page 66. new product launches and R&D have been factored into They use words such as anticipate, estimate, expect, the expectations given.
The expectations are given on a intend, will, project, plan, believe and other words The information in this document does not constitute constant currency basis and assume no material change and terms of similar meaning in connection with any an offer to sell or an invitation to buy shares in to the Groups effective tax rate.
discussion of future operating or financial performance.
GlaxoSmithKline plc or an invitation or inducement In particular, these include statements relating to future to engage in any other investment activities.
Past Notice regarding limitations on actions, prospective products or product approvals, performance cannot be relied upon as a guide to Director Liability under English Law future performance or results of current and anticipated future performance.
Nothing in this Annual Report Under the UK Companies Act 2006, a safe harbour limits products, sales efforts, expenses, the outcome of should be construed as a profit forecast.
the liability of Directors in respect of statements in and contingencies such as legal proceedings, and financial omissions from the Directors Report for which see Assumptions related to 2016-2020 outlook results.
Other than in accordance with its legal or page 101, the Strategic report and the Remuneration regulatory obligations including under the UK Listing In outlining the expectations for the five-year period report.
Under English law the Directors would be liable to Rules and the Disclosure and Transparency Rules of the 2016-2020, the Group has made certain assumptions the company, but not to any third party, if one or more of Financial Conduct Authority, the Group undertakes no about the healthcare sector, the different markets in these reports contained errors as a result of recklessness obligation to update any forward-looking statements, which the Group operates and the delivery of revenues or knowing misstatement or dishonest concealment of a whether as a result of new information, future events and financial benets from its current portfolio, pipeline material fact, but would otherwise not be liable.
The reader should, however, consult any and restructuring programmes.
to 110, 148, 232 and 253 to 282 inclusive comprise the additional disclosures that the Group may make in any Directors Report, pages 2 to 78 inclusive comprise the For the Group specically, over the period to 2020 documents which it publishes and or les with the SEC.
Strategic report and pages 111 to 146 inclusive comprise GSK expects further declines in sales of Seretide Advair.
All readers, wherever located, should take note of these the Remuneration report, each of which have been drawn The introduction of a generic alternative to Advair in the disclosures.
Accordingly, no assurance can be given that up and presented in accordance with and in reliance upon US has been factored into the Groups assessment of its any particular expectation will be met and shareholders English company law and the liabilities of the Directors future performance.
The Group assumes no premature are cautioned not to place undue reliance on the forwardin connection with these reports shall be subject to the loss of exclusivity for other key products over the period.
limitations and restrictions provided by such law.
The Groups expectation of at least 6 billion of revenues Forward-looking statements are subject to assumptions, per annum on a CER basis by 2020 from products Website inherent risks and uncertainties, many of which relate to launched in the last three years includes contributions GSKs website www.
com gives additional information factors that are beyond the Groups control or precise from the current pipeline asset Shingrix.
This target is on the Group.
Notwithstanding the references we make estimate.
The Group cautions investors that a number now expected to be met up to two years earlier.
The in this Annual Report to GSKs website, none of the of important factors, including those in this document, Group also expects volume demand for its products information made available on the website constitutes could cause actual results to differ materially from those to increase, particularly in Emerging Markets.
part of this Annual Report or shall be deemed to be expressed or implied in any forward-looking statement.
Head Ofce and Registered Ofce GlaxoSmithKline plc 980 Great West Road Brentford, Middlesex TW8 9GS United Kingdom Tel: 44 0 20 8047 5000 Registered number: 3888792 www.
